Commerce Bank lifted its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 9.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,790 shares of the biopharmaceutical company’s stock after purchasing an additional 695 shares during the quarter. Commerce Bank’s holdings in Regeneron Pharmaceuticals were worth $3,804,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also modified their holdings of REGN. AE Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter worth approximately $219,000. Janney Montgomery Scott LLC boosted its stake in Regeneron Pharmaceuticals by 136.9% in the fourth quarter. Janney Montgomery Scott LLC now owns 6,901 shares of the biopharmaceutical company’s stock worth $2,591,000 after buying an additional 3,988 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Regeneron Pharmaceuticals by 3.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,128 shares of the biopharmaceutical company’s stock worth $7,558,000 after buying an additional 577 shares in the last quarter. Wealthfront Advisers LLC purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter worth approximately $267,000. Finally, Exchange Traded Concepts LLC purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter worth approximately $88,000. 66.58% of the stock is owned by institutional investors.
In other news, Director George L. Sing sold 5,000 shares of the stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $580.00, for a total value of $2,900,000.00. Following the sale, the director now directly owns 120,415 shares of the company’s stock, valued at $69,840,700. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Christopher R. Fenimore sold 1,200 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $488.41, for a total value of $586,092.00. Following the completion of the sale, the vice president now directly owns 14,297 shares in the company, valued at $6,982,797.77. The disclosure for this sale can be found here. In the last quarter, insiders sold 196,397 shares of company stock valued at $109,206,506. 11.84% of the stock is owned by corporate insiders.
Several analysts have issued reports on the company. Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 31st. They issued a “market perform” rating and a $455.00 target price for the company. SunTrust Banks boosted their price objective on Regeneron Pharmaceuticals to $400.00 and gave the company a “hold” rating in a research report on Friday, February 7th. JPMorgan Chase & Co. boosted their price objective on Regeneron Pharmaceuticals from $375.00 to $429.00 and gave the company a “neutral” rating in a research report on Wednesday, April 15th. Jefferies Financial Group upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price objective for the company from $355.00 to $492.00 in a research report on Tuesday, February 25th. Finally, Argus boosted their price objective on Regeneron Pharmaceuticals from $430.00 to $540.00 and gave the company a “buy” rating in a research report on Thursday, March 12th. Fourteen analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $515.26.
REGN opened at $569.91 on Friday. The stock has a fifty day simple moving average of $541.71 and a two-hundred day simple moving average of $427.59. The company has a current ratio of 4.21, a quick ratio of 3.49 and a debt-to-equity ratio of 0.06. The company has a market cap of $61.72 billion, a price-to-earnings ratio of 28.64, a price-to-earnings-growth ratio of 1.23 and a beta of 0.53. Regeneron Pharmaceuticals Inc has a 12-month low of $271.37 and a 12-month high of $583.54.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $6.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.13 by $0.47. The business had revenue of $1.83 billion during the quarter, compared to the consensus estimate of $1.81 billion. Regeneron Pharmaceuticals had a return on equity of 24.94% and a net margin of 28.56%. The firm’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $4.45 earnings per share. On average, analysts predict that Regeneron Pharmaceuticals Inc will post 23.84 EPS for the current year.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Article: How do taxes affect a CDs total return?
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.